Related Experiment Video
Updated: May 30, 2026

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus
Published on: January 28, 2019
Monovalent rotavirus vaccine provides protection against an emerging fully heterotypic G9P[4] rotavirus strain in
Catherine Yen1, Jesùs Reyna Figueroa, Edgar Sánchez Uribe
1Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. cyen@cdc.go
Abstract:
After the introduction of monovalent rotavirus vaccine (RV1) in Mexico in 2006-2007, diarrhea mortality and morbidity declined substantially among Mexican children under 5 years of age. In January 2010, surveillance identified the emergence of a novel G9P[4] rotavirus strain nationwide. We conducted a case-control study to assess the field effectiveness of RV1 against severe rotavirus gastroenteritis caused by this unusual strain and to determine whether the G9P[4] emergence was related to vaccine failure or failure to vaccinate. RV1 was 94% effective (95% confidence interval, 16%-100%) against G9P[4] rotavirus-related hospitalization, indicating that its emergence was likely unrelated to vaccine pressure.
Related Concept Videos
Poliomyelitis
Respiratory Syncytial Virus Disease
Vaccinations
Bacterial Gastroenteritis
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

